Intimation of Investor presentation for the analyst/institutional investor meeting to be held for financial result of quarter ended 30th June 2026.

INNOVA CAPTAB LIMITED Plot No. 320, Industrial Area, Phase-1, Panchkula, Pin-134113, Haryana, India. Phone: +91-172-4194500 11th August, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Mumbai – 400001 Bandra Kurla Complex BSE Symbol: INNOVACAP Bandra (E), Mumbai – 400051 BSE Scrip Code: 544067 NSE Symbol: INNOVACAP Dear Sir/Madam, Subject: Intimation of investor presentation for the analysts/ institutional Investor meeting to be held for financial results of the quarter ended 30th June, 2026 This is in continuation to our intimation dated 07th August, 2026 wherein we had informed regarding an earnings call scheduled with analysts / investors on Wednesday, 12th August, 2026 at 11:00 A.M. (IST) to discuss the unaudited financial results for the quarter ended 30th June, 2026. Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”) as amended, please find enclosed herewith the investor presentation for the said earnings call. This is for your information and record. Thanking you, Yours faithfully, For Innova Captab Limited Neeharika Shukla Company Secretary and Compliance Officer Encl.: A/a Registered Office - 1513, 15th Floor, Satra Plaza CHS Ltd. Plot No. 19&20, Sector-19D, Vashi, Navi Mumbai-400703, Maharashtra, India. CIN - L24246MH2005PLC150371, email - mail@innovacaptab.com G R O W T H BUILT ON CONSISTENCY Investor Presentation – August 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward-looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company. C o m p a n y O v e r v i e w Leading Pharmaceutical Player with Comprehensive Business Model Robust Financials Preferred CDMO partner for prominent pharmaceutical companies worldwide, with a strong direct (FY26) presence across geographies through our branded generics business Revenues ₹ 1,630 Cr EBITDA 350 + 60+ Comprehensive portfolio ₹ 250 Cr Presence across CDMO Customers across 4,200+ of products (15.4%) countries the Globe ₹ 141 Cr (8.6%) ROCE Serving some 14.5% Strong network of prominent of the 2,50,000+ Pharmaceutical companies touchpoints in India globally Transforming Vision into Milestones of Growth 2006 2013 2025 2017 Foundation 2022 International GMP Commercialization of The journey commenced with Certification Establishment of G Strategic Expansion manufacturing facility in the establishment of the first Block Kathua, Jammu manufacturing facility in Global quality credentials were Expansion plans were accelerated Baddi, Himachal Pradesh, strengthened with the receipt of GMP Initiated operations at the with the initiation of a Commercial operations at our state-of- marking our Company’s entry certification for cephalosporin products newly established G Block manufacturing facility in Kathua, the-art manufacturing facility in into pharmaceutical from the Ministry of Medical Services, facility within the Baddi Jammu. Kathua, Jammu commenced in January Republic of Kenya. plant. 2025, marking a significant milestone manufacturing. in our capacity expansion journey. 2010 2015 2026 2021 Establishment of 2023 Establishment of Global Cephalosporin Plant Further Marketing Arm Acquisition & IPO Certifications Expansion A dedicated cephalosporin Marketing and operational Milestones Received Certificate of GMP block was commissioned at capabilities were expanded The capacity of the G Block the Baddi facility, enhancing Capabilities and product Compliance by UK-MHRA for through the incorporation was expanded to support manufacturing capabilities offerings were Cephalosporin, Baddi facility of Univentis Medicare growing demand and and product depth. strengthened through the and received Certificate of Limited. improve operational acquisition of Sharon, GMP Compliance from PIC/S throughput. followed by the successful (SMDC, Ukraine) for Kathua, listing on stock exchanges. Jammu facility. With State-of-the-Art Manufacturing Facilities Key Accreditations Manufacturing Blocks Kathua, Jammu [4 Blocks] 3 Baddi |1 Dehradun |1 Taloja | 4 Jammu Upcoming R&D Baddi, Himachal Pradesh (2 Units) [3 Blocks] Facility in R&D Facility in Baddi, Himachal Pradesh Panchkula, Haryana Dehradun, Uttarakhand (1 Unit) New Greenfield Multipurpose Facility (4 manufacturing blocks) in Kathua, Jammu commercialized in Jan’25 Among the largest Taloja, Maharashtra (1 Unit) Finished Tablet and Capsule Manufacturing Capacity in India Manufacturing Unit R&D Center High FATR Track record of operating at high Fixed Asset Turnover Ratio Disclaimer: This map is a generalized illustration only for the ease of the reader to understand the locations, and it is not intended to be used for reference purposes. The representation of political boundaries and the names of geographical features/states do not necessarily reflect the actual position. Our Company or any of our Directors, officers or employees cannot be held responsible for any misuse or misinterpretation of any information or design thereof. Our Company does not warrant or represent any kind of connection with its accuracy or completeness. Disciplined Capital Allocation Driving Sustainable Growth FY23 FY26 Growth (₹ in Crs) 150 780 ~5x Fixed Assets 926 1,630 ~2x Revenue EBITDA 123 250 ~2x Profit After Tax 68 141 Q 1 F Y 2 7 P e r f o r m a n c e H i g h l i g h t s MD’s Commentary Innova Captab Limited delivered a strong start to FY27, with revenue and EBITDA growing by 34% and 33% YoY, respectively. The performance underscores the continued strength of our diversified business model, disciplined execution and sustained customer traction across both our CDMO Services & Products and Branded Generics businesses. Growth during the quarter was supported by steady order flows, a broader product portfolio and deeper engagement with existing and [Showing first 8,000 characters — download PDF for full document]